Opioid-Free vs Opioid Analgesia for Postoperative Pain
(PAIN-Alt Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether pain relief without opioids can match the effectiveness of opioids after breast surgery. The aim is to determine if avoiding opioids can prevent addiction and misuse while still effectively managing pain. Participants will join one of two groups: one will receive opioid analgesia (opioid painkillers), and the other will receive only non-opioid medications. This study suits those undergoing breast surgery, such as mastectomy or lumpectomy, who plan to go home the same day. The findings could guide doctors in deciding when opioids are necessary for post-surgery pain management. As an unphased trial, it offers patients the chance to contribute to research that could lead to safer pain management options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are taking opioids before the surgery, you cannot participate in the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Studies have shown that opioid-free analgesia (OFA), which manages pain without opioids, is safe for patients after surgery. Research indicates that OFA aids recovery without harmful effects. In several studies, patients using OFA experienced similar pain levels to those using opioids but had fewer side effects like nausea and vomiting.
Opioids are well-known painkillers but carry risks. Common side effects include drowsiness, dizziness, and nausea, along with the risk of misuse or addiction.
Both treatments have undergone safety studies, but OFA may help avoid the risks associated with opioids.12345Why are researchers excited about this trial?
Researchers are excited about opioid-free analgesia (OFA) for postoperative pain because it offers a way to manage pain without the risks associated with opioids, like addiction and side effects. Unlike traditional opioid analgesia, OFA uses non-opioid medications and techniques to control pain effectively, potentially reducing the reliance on opioids. This approach could lead to safer postoperative recovery and a significant reduction in opioid-related complications. By exploring OFA, researchers hope to find a safer pain management strategy that doesn't compromise on effectiveness.
What evidence suggests that this trial's treatments could be effective for postoperative pain?
This trial will compare Opioid-Free Analgesia (OFA) with Opioid Analgesia (OA) for managing postoperative pain. Studies have shown that opioid-free pain treatments can be as effective as opioid-based treatments for managing post-surgical pain. Research indicates that individuals using opioid-free pain relief often experience less nausea and vomiting after surgery, aiding faster recovery. One study found that pain levels 24 hours post-surgery were similar between those who received opioid-free treatments and those who received opioids. These findings suggest that opioid-free options might offer effective pain relief without the addiction risk associated with opioids.23678
Who Is on the Research Team?
Julio Flavio Fiore, PhD
Principal Investigator
McGill University
Are You a Good Fit for This Trial?
This trial is for patients having outpatient breast surgery (mastectomy or lumpectomy) for cancerous or non-cancerous conditions, with plans to go home the same day. It's not specified who can't join.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either opioid or non-opioid analgesia after outpatient breast surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Assessment of chronic postsurgical pain and persistent opioid use
What Are the Treatments Tested in This Trial?
Interventions
- Opioid Analgesia (OA)
- Opioid-Free Analgesia (OFA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator